Article Figures & Data
Figures
- FIGURE 1.
(A) Representative whole-body anterior projection images of a 61-y-old male patient with NET liver metastases at 2, 24, 72, 120, and 168 h after intravenous administration of 177Lu-DOTA-EB-TATE. 177Lu-DOTA-EB-TATE cleared from blood pool over time and persistently accumulated in tumors. (B) Representative whole-body anterior projection images of a 49-y-old male patient with NET liver metastases at 1, 3, 4, 24, and 72 h after intravenous administration of 177Lu-DOTATATE. 177Lu-DOTATATE showed rapid renal clearance. Tumor uptake also gradually decreased along with time.
- FIGURE 2.
(A) Blood clearance of 177Lu-DOTA-EB-TATE quantified by SPECT and γ-counting of blood samples. (B) There is positive linear correlation between SPECT quantification and blood sampling (R2 = 0.90, P < 0.0001).
- FIGURE 3.
68Ga-DOTATATE PET/CT and 177Lu-DOTA-EB-TATE whole-body planar imaging and SPECT/CT of a 45-y-old male NET patient with multiple liver metastases. (A) Liver metastases identified by 68Ga-DOTATATE PET were clearly visualized on whole-body anteroposterior projection image at 1 d after administration of 177Lu-DOTA-EB-TATE. (B) Liver metastases were still clearly visualized on whole-body anteroposterior projection image at 7 d after administration of 177Lu-DOTA-EB-TATE. (C and D) Multiple liver metastases were shown on axial PET image (C) and PET/CT (D) at 45 min after intravenous injection of 68Ga-DOTATATE.
- FIGURE 4.
68Ga-DOTATATE PET/CT and 177Lu-DOTATATE whole-body planar imaging and SPECT/CT in a 27-y-old woman with advanced NET (G2). Multiple liver metastases were shown on whole-body anteroposterior projection images at 3 h (A) and 3 d (B) after administration of 177Lu-DOTATATE. Same liver metastases were shown on axial PET (C) and PET/CT (D) at 45 min after intravenous injection of 68Ga-DOTATATE.
- FIGURE 5.
(A) Time–activity curves of NET lesions after administration of 177Lu-DOTA-EB-TATE (blue) and 177Lu-DOTATATE (red). (B) Number of disintegration of 177Lu within NET lesions from 177Lu-DOTA-EB-TATE and 177Lu-DOTATATE.
Tables
- TABLE 1
Biodistribution of 177Lu-DOTA-EB-TATE (SUV, n = 5) and 177Lu-DOTATATE (SUV, n = 3) in Patients with Advanced NETs
177Lu-DOTA-EB-TATE 177Lu-DOTA-TATE Organ 2 h 24 h 72 h 168 h 1 h 3 h 24 h 72 h Blood 3.39 ± 1.17 1.75 ± 0.58 1.29 ± 0.44 0.94 ± 0.30 0.17 ± 0.04 0.15 ± 0.02 0.09 ± 0.03 0.03 ± 0.00 Lung 0.41 ± 0.14 0.25 ± 0.09 0.21 ± 0.06 0.14 ± 0.06 0.07 ± 0.02 0.06 ± 0.01 0.05 ± 0.01 0.04 ± 0.01 Liver 1.82 ± 0.73 1.39 ± 0.46 1.27 ± 0.45 1.07 ± 0.41 1.39 ± 0.12 1.25 ± 0.18 0.94 ± 0.09 0.85 ± 0.20 Spleen 3.24 ± 1.50 3.34 ± 1.97 3.54 ± 2.67 3.57 ± 2.97 4.21 ± 0.22 3.93 ± 0.32 3.42 ± 0.52 3.70 ± 0.74 Pancreas 2.23 ± 0.68 1.62 ± 0.45 1.18 ± 0.32 0.98 ± 0.21 0.85 ± 0.23 0.76 ± 0.18 0.57 ± 0.25 0.60 ± 0.22 Kidneys 2.67 ± 0.89 3.03 ± 1.22 3.20 ± 1.86 2.47 ± 1.49 1.78 ± 0.38 1.54 ± 0.22 1.14 ± 0.19 1.13 ± 0.15 Muscle 0.11 ± 0.03 0.17 ± 0.03 0.14 ± 0.04 0.10 ± 0.03 0.09 ± 0.02 0.08 ± 0.03 0.07 ± 0.02 0.07 ± 0.02 Data are mean ± SD.
- TABLE 2
Estimated Effective Dose After Intravenous Administration of 177Lu-NOTA-EB-TATE (n = 5, 4 Men and 1 Woman) and 177Lu-DOTATATE (n = 3, 2 Men and 1 Woman)
Target organ 177Lu-DOTA-EB-TATE (mSv/MBq) 177Lu-DOTATATE (mSv/MBq) Adrenals 0.0099 ± 0.0062 0.0063 ± 0.0023 Brain 0.0004 ± 0.0001 0.0002 ± 0.0001 Breasts 0.0016 ± 0.0006 0.0010 ± 0.0004 Gallbladder wall 0.0106 ± 0.0046 0.0068 ± 0.0024 Lower large intestine wall 0.0032 ± 0.0013 0.0020 ± 0.0007 Small intestine 0.1596 ± 0.0698 0.0712 ± 0.0171 Stomach wall 0.0896 ± 0.0317 0.0501 ± 0.0121 Upper large intestine wall 0.0062 ± 0.0029 0.0035 ± 0.0010 Heart wall 0.1918 ± 0.0512 0.0475 ± 0.0308 Kidneys 1.1494 ± 0.9183 0.3603 ± 0.0677 Liver 0.3468 ± 0.1531 0.2247 ± 0.0954 Lungs 0.0479 ± 0.0178 0.0095 ± 0.0033 Muscle 0.0375 ± 0.0159 0.0260 ± 0.0137 Ovaries 0.0040 ± 0.0016 0.0023 ± 0.0008 Pancreas 0.2872 ± 0.1044 0.4143 ± 0.1153 Red marrow 0.0582 ± 0.0137 0.0032 ± 0.0004 Osteogenic cells 0.0329 ± 0.0118 0.0033 ± 0.0009 Skin 0.0013 ± 0.0005 0.0009 ± 0.0003 Spleen 1.4470 ± 1.5894 1.7693 ± 0.9450 Testes 0.0011 ± 0.0003 0.0010 ± 0.0005 Thymus 0.0026 ± 0.0008 0.0015 ± 0.0006 Thyroid 0.0015 ± 0.0004 0.0010 ± 0.0005 Urinary bladder wall 0.0204 ± 0.0141 0.0635 ± 0.0388 Total body 0.0370 ± 0.0176 0.0243 ± 0.0089 Effective dose equivalent 0.2048 ± 0.1605 0.1735 ± 0.0722 Effective dose 0.0804 ± 0.0500 0.0693 ± 0.0317 Data are mean ± SD.
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Landscape of Nuclear Medicine in China and Its Progress on Theranostics
- Efficacy of [67Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2-Positive Neuroendocrine Tumors
- A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
- Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic
- Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
- 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
- Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE
- Reply: Different Radionuclides in DOTA-EB-TATE Effect Different Uptake in Somatostatin Receptor-Positive HEK293 Cells
- Different Radionuclides in DOTA-EB-TATE Effect Different Uptake in Somatostatin Receptor-Positive HEK293 Cells
- Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients
- New Developments in Peptide Receptor Radionuclide Therapy